| Literature DB >> 28728591 |
Subarna Dutta1, Sabah Haq2, Mohammad Rokibul Hasan1, Jalaluddin Ashraful Haq3.
Abstract
BACKGROUND: Melioidosis an infectious disease, caused by a Gram negative bacterium called Burkholderia pseudomallei, is endemic in Bangladesh. This organism is sensitive to limited number of antimicrobial agents and need prolonged treatment. There is no comprehensive data on the antimicrobial susceptibility profile of B. pseudomallei isolated in Bangladesh over last several years. The present study aimed to determine the antimicrobial susceptibility pattern of B. pseudomallei isolated in a tertiary care hospital of Dhaka city from 2009 to 2015.Entities:
Keywords: Antimicrobial susceptibility; Bangladesh; Burkholderia pseudomallei; Minimum inhibitory concentration
Mesh:
Substances:
Year: 2017 PMID: 28728591 PMCID: PMC5520358 DOI: 10.1186/s13104-017-2626-5
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Zone diameter interpretive standards and MIC breakpoints for B. pseudomallei used in the study
| Antimicrobial agents | Disk diffusion test | MIC (µg/ml) | |||||
|---|---|---|---|---|---|---|---|
| Disk content (µg) | Zone diameter (mm) | ||||||
| R | I | S | S | I | R | ||
| Ceftazidimea, b | 30 | ≤14 | 15–16 | ≥18 | ≤8 | 16 | ≥32 |
| Imipenema, b | 10 | ≤15 | 16–18 | ≥19 | ≤4 | 8 | ≥16 |
| Amox–Clava,d | 20/10 | ≤13 | 14–17 | ≥18 | ≤8/4 | 16/8 | ≥32/16 |
| Pip–Tazob, c | 100/10 | ≤14 | 15–20 | ≥21 | ≤16/4 | 32/4–64/4 | ≥128/4 |
| TMP–SMXa, d | 1.25/23.75 | ≤10 | 11–15 | ≥16 | ≤2/38 | – | ≥4/76 |
| Tetracyclinea, d | 30 | ≤11 | 12–14 | ≥15 | ≤4 | 8 | ≥16 |
| Amikacinb, c | 30 | ≤14 | 15–16 | ≥17 | ≤16 | 32 | ≥64 |
| Gentamicinb, c | 10 | ≤12 | 13–14 | ≥15 | ≤4 | 8 | ≥16 |
TMP–SMX trimethoprim/sulfamethoxazole, Pip–Tazo piperacillin–tazobactam, Amox–Clav amoxicillin/clavulanic acid, MIC minimum inhibitory concentration
aMIC interpretive standards defined in M45-A2, CLSI guideline for B. pseudomallei [19]
bZone diameter interpretive standards of CLSI for P. aeruginosa by disk diffusion method [20]
cMIC interpretive standard of CLSI for P. aeruginosa [20]
dZone diameter interpretive standards of CLSI for Enterobacteriaceae by disk diffusion method [20]
Results of disk diffusion and MIC tests of B. pseudomallei isolated during 2009–2015 (N = 20)
| Antimicrobial agents | Disk diffusion test | MIC test | ||||
|---|---|---|---|---|---|---|
| Disk content (µg) | Sensitive | Zone diameter range (mm) | Sensitive | MIC50 (µg/ml) | MIC90 (µg/ml) | |
| Ceftazidime | 30 | 20 (100) | 24–32 | 20 (100) | 2 | 2 |
| Imipenem | 10 | 20 (100) | 33–40 | 20 (100) | 2 | 2 |
| Amox–Clav | 20/10 | 20 (100) | 19–28 | 20 (100) | 8/4 | 8/4 |
| Pip–Tazo | 100/10 | 20 (100) | 35–39 | 20 (100) | 2/4 | 2/4 |
| TMP–SMX | 1.25/23.75 | 18 (90) | 15–28 | 20 (100) | 1/19 | 2/38 |
| Tetracycline | 30 | 20 (100) | 17–31 | 20 (100) | 0.5 | 1 |
| Amikacin | 30 | 0 (0) | 10–15 | 0 (0) | 64 | 64 |
| Gentamicin | 10 | 0 (0) | 0 | ND | ND | ND |
TMP–SMX trimethoprim/sulfamethoxazole, Pip–Tazo piperacillin–tazobactam, Amox–Clav amoxicillin/clavulanic acid, MIC minimum inhibitory concentration, ND not done